

Author index

Volume 54 (1999)

- Agrawal, S. 54, 259
Alper, K.R. 54, 35
Alterman, A.I. 54, 11, 111
Anthony, J.C. 54, 117
- Barber, W. 54, 111
Bedi, N. 54, 111
Booth, R.E. 54, 57
Borg, L. 54, 87
Brown, L.S., Jr. 54, 11
- Cacciola, J. 54, 11
Caetano, R. 54, 45
Carneiro, M. 54, 83
Carroll, K.M. 54, 171
Charnaud, B. 54, 179
Chutuape, M.A. 54, 69
Clark, C.L. 54, 45
Cleland, P.A. 54, 259
Cnaan, A. 54, 11, 111
Compton, W.M. 54, 1
Cottler, L.B. 54, 1
Coutinho, R.A. 54, 145
Cunningham-Williams, R.M. 54, 1
- Darke, S. 54, 155
Dawson, D.A. 54, 219
Deichler, P. 54, 1
DeJesus, A. 54, 127
Delete, P. 54, 91
Desmond, D.P. 54, 1
Doherty, M.C. 54, 83
- Ellingstad, T.P. 54, 259
Epstein, J.F. 54, 229
- Fisher, K.J. 54, 251
Flynn, C. 54, 145
Foote, J. 54, 207
France, C.P. 54, 137, 239
Fuller, C. 54, 83
- Gariti, P. 54, 111
Gerak, L.R. 54, 137
Gfroerer, J.C. 54, 229
Gillespie, A.M. 54, 251
Griffiths, V. 54, 179
- Hall, W. 54, 155
Handelsman, L. 54, 207
Ho, A. 54, 87
Horner, M.D. 54, 19
- John, E.R. 54, 35
- King, A.C. 54, 87
Kowalik, S.C. 54, 35
Kreek, M.J. 54, 87
Krol, A. 54, 145
Kwiatkowski, C.F. 54, 57
- Lelas, S. 54, 239
Lind, B. 54, 155, 163
Lowe, J.B. 54, 251
Luck, G. 54, 111
- Mach, R.H. 54, 97
Magura, S. 54, 207
McKay, J.R. 54, 171
McLellan, A.T. 54, 171
Merkin, H.A. 54, 35
Miedema, F. 54, 145
Montoya, I.D. 54, 127
Mulvaney, F.D. 54, 11
- Nader, M.A. 54, 97
Nich, C. 54, 171
- Otton, S.V. 54, 239
- Palij, M. 54, 207
Polcin, D.L. 54, 63
Preston, K.L. 54, 127
- Pritchep, L.S. 54, 35
- Rose, J.M. 54, 251
Rosenblum, A. 54, 207
Rosenthal, M.S. 54, 35
Rounsaville, B.J. 54, 171
Rowlett, J.K. 54, 137
Rutherford, M. 54, 11
- Sage, R.E. 54, 11
Schluger, J. 54, 87
Schuster, C.R. 54, 127
Sellers, E.M. 54, 239
Silverman, K. 54, 69, 127
Sinnott, R.S. 54, 97
Sobell, L.C. 54, 259
Sobell, M.B. 54, 259
Stanton, W.R. 54, 251
Stevenson, R.J. 54, 163
Stimmel, B. 54, 207
Stitzer, M. 54, 69
Stober, D.R. 54, 57
- Tom, M.L. 54, 35
- Umbricht, A. 54, 127
- van Ameijden, E.J.C. 54, 145
Van Etten, M.L. 54, 117
Vaysblat, L.S. 54, 35
Vlahov, D. 54, 83, 145
- Weatherburn, D. 54, 155, 163
Wechsberg, W. 54, 1
Wegert, S. 54, 239
Weisner, C. 54, 63
Winger, G. 54, 137
Woods, J.H. 54, 137
Woolverton, W.L. 54, 137
- Zhang, Y. 54, 57
Zule, W.A. 54, 1

Subject index

Volume 54 (1999)

Aboriginals; Alcohol; Crime; Malicious-damage; Offensive-behaviour **54, 163**

Abuse potential; Gamma-hydroxybutyrate; Rhesus monkeys; Self-administration; Drug discrimination; Dependence potential **54, 137**

Addiction Severity Index; Coercion; Pressure to enter treatment; Ultimatum **54, 63**

κ Agonist; Dynorphin; Opioid; Subjective effects **54, 87**

Alcohol; Aboriginals; Crime; Malicious-damage; Offensive-behaviour **54, 163**

Alcohol abuse; Alcohol dependence; Nicotine; Smoking; Treatment **54, 259**

Alcohol dependence; Alcohol abuse; Nicotine; Smoking; Treatment **54, 259**

Alcohol; Norms; Attitudes; Ethnicity; Blacks; Hispanics **54, 45**

Antinociception; Hydrocodone; P450 enzymes; Drug discrimination; Rhesus monkey **54, 239**

Attention; Cocaine; Neuropsychology; Cognition **54, 19**

Attitudes; Alcohol; Norms; Ethnicity; Blacks; Hispanics **54, 45**

Benzodiazepines; Contingency management; Detoxification; Methadone; Vouchers **54, 69**

Blacks; Alcohol; Norms; Attitudes; Ethnicity; Hispanics **54, 45**

CD4+ lymphocyte decline; Drug users; HIV; Heroin; Substance abuse **54, 145**

Cessation; Smoking; Youth; Unemployed; Student **54, 251**

Clinical trial; Cocaine treatment; Methadone treatment; Treatment efficacy **54, 207**

Clinical trials; Cocaine treatment; Generalizability **54, 171**

Cocaine dependence; Subtypes; Treatment outcome; Electrophysiology; QEEG; Neurometrics; Comorbidity **54, 35**

Cocaine; Neuropsychology; Attention; Cognition **54, 19**

Cocaine; Quinpirole; 7-OH-DPAT; Self-administration; Drug discrimination; Dopamine receptors; Rhesus monkey **54, 97**

Cocaine treatment; Generalizability; Clinical trials **54, 171**

Cocaine treatment; Methadone treatment; Clinical trial; Treatment efficacy **54, 207**

Coercion; Addiction Severity Index; Pressure to enter treatment; Ultimatum **54, 63**

Cognition; Cocaine; Neuropsychology; Attention **54, 19**

Comorbidity; Cocaine dependence; Subtypes; Treatment outcome; Electrophysiology; QEEG; Neurometrics **54, 35**

Condom use; Heterosexually active drug users; HIV intervention; Sex risk **54, 57**

Contingency management; Detoxification; Methadone; Vouchers; Benzodiazepines **54, 69**

Contingency management; Naltrexone; Opioid-dependence; Treatment; Treatment compliance **54, 127**

Cotinine replacement; Smokers; Patch treatment **54, 111**

Crime; Aboriginals; Alcohol; Malicious-damage; Offensive-behaviour **54, 163**

Dependence potential; Gamma-hydroxybutyrate; Rhesus monkeys; Self-administration; Drug discrimination; Abuse potential **54, 137**

Detoxification; Contingency management; Methadone; Vouchers; Benzodiazepines **54, 69**

Dopamine receptors; Cocaine; Quinpirole; 7-OH-DPAT; Self-administration; Drug discrimination; Rhesus monkey **54, 97**

Driving; Ethanol intake; Heavy drinking days **54, 219**

Drug abuse treatment; Marijuana; Future treatment needs **54, 229**

Drug discrimination; Cocaine; Quinpirole; 7-OH-DPAT; Self-administration; Dopamine receptors; Rhesus monkey **54, 97**

Drug discrimination; Gamma-hydroxybutyrate; Rhesus monkeys; Self-administration; Abuse potential; Dependence potential **54, 137**

Drug discrimination; Hydrocodone; P450 enzymes; Antinociception; Rhesus monkey **54, 239**

- Drug users;** CD4 + lymphocyte decline; HIV; Heroin; Substance abuse 54, 145
- Dynorphin;** Opioid; κ Agonist; Subjective effects 54, 87
- Electrophysiology;** Cocaine dependence; Subtypes; Treatment outcome; QEEG; Neurometrics; Comorbidity 54, 35
- Equivalence;** Substance abuse; Methadone-maintenance; Race; Gender 54, 11
- Ethanol intake;** Driving; Heavy drinking days 54, 219
- Ethnicity;** Alcohol; Norms; Attitudes; Blacks; Hispanics 54, 45
- Fatal overdose;** Heroin purity; South western Sydney 54, 155
- Future treatment needs;** Marijuana; Drug abuse treatment 54, 229
- Gamma-hydroxybutyrate;** Rhesus monkeys; Self-administration; Drug discrimination; Abuse potential; Dependence potential 54, 137
- Gender;** Substance abuse; Methadone-maintenance; Race; Equivalence 54, 11
- Generalizability;** Cocaine treatment; Clinical trials 54, 171
- Heavy drinking days;** Ethanol intake; Driving 54, 219
- Heroin;** CD4 + lymphocyte decline; Drug users; HIV; Substance abuse 54, 145
- Heroin purity;** Fatal overdose; South western Sydney 54, 155
- Heterosexually active drug users;** Condom use; HIV intervention; Sex risk 54, 57
- Hispanics;** Alcohol; Norms; Attitudes; Ethnicity; Blacks 54, 45
- HIV/AIDS prevention;** Substance abuse; Street outreach; Recruitment 54, 1
- HIV;** CD4 + lymphocyte decline; Drug users; Heroin; Substance abuse 54, 145
- HIV intervention;** Condom use; Heterosexually active drug users; Sex risk 54, 57
- Human immunodeficiency virus;** Substance abuse; Intravenous 54, 83
- Hydrocodone;** P450 enzymes; Drug discrimination; Antinociception; Rhesus monkey 54, 239
- Illicit drugs;** NHSDA; Opportunity; Transitions; Sex differences 54, 117
- Intravenous;** Substance abuse; Human immunodeficiency virus 54, 83
- Malicious-damage;** Aboriginals; Alcohol; Crime; Offensive-behaviour 54, 163
- Marijuana;** Drug abuse treatment; Future treatment needs 54, 229
- Methadone;** Contingency management; Detoxification; Vouchers; Benzodiazepines 54, 69
- Methadone-maintenance;** Substance abuse; Race; Gender; Equivalence 54, 11
- Methadone treatment;** Cocaine treatment; Clinical trial; Treatment efficacy 54, 207
- Naltrexone;** Opioid-dependence; Treatment; Contingency management; Treatment compliance 54, 127
- Neurometrics;** Cocaine dependence; Subtypes; Treatment outcome; Electrophysiology; QEEG; Comorbidity 54, 35
- Neuropsychology;** Cocaine; Attention; Cognition 54, 19
- NHSDA;** Illicit drugs; Opportunity; Transitions; Sex differences 54, 117
- Nicotine;** Alcohol abuse; Alcohol dependence; Smoking; Treatment 54, 259
- Norms;** Alcohol; Attitudes; Ethnicity; Blacks; Hispanics 54, 45
- Offensive-behaviour;** Aboriginals; Alcohol; Crime; Malicious-damage 54, 163
- 7-OH-DPAT;** Cocaine; Quinpirole; Self-administration; Drug discrimination; Dopamine receptors; Rhesus monkey 54, 97
- Opioid-dependence;** Naltrexone; Treatment; Contingency management; Treatment compliance 54, 127
- Opioid;** Dynorphin; κ Agonist; Subjective effects 54, 87
- Opportunity;** Illicit drugs; NHSDA; Transitions; Sex differences 54, 117
- Patch treatment;** Smokers; Cotinine replacement 54, 111
- P450 enzymes;** Hydrocodone; Drug discrimination; Antinociception; Rhesus monkey 54, 239
- Pressure to enter treatment;** Addiction Severity Index; Coercion; Ultimatum 54, 63
- QEEG;** Cocaine dependence; Subtypes; Treatment outcome; Electrophysiology; Neurometrics; Comorbidity 54, 35
- Quinpirole;** Cocaine; 7-OH-DPAT; Self-administration; Drug discrimination; Dopamine receptors; Rhesus monkey 54, 97
- Race;** Substance abuse; Methadone-maintenance; Gender; Equivalence 54, 11
- Recruitment;** Substance abuse; HIV/AIDS prevention; Street outreach 54, 1
- Rhesus monkey;** Cocaine; Quinpirole; 7-OH-DPAT; Self-administration; Drug discrimination; Dopamine receptors 54, 97
- Rhesus monkey;** Hydrocodone; P450 enzymes; Drug discrimination; Antinociception 54, 239

- Rhesus monkeys**; Gamma-hydroxybutyrate; Self-administration; Drug discrimination; Abuse potential; Dependence potential **54**, 137
- Self-administration**; Cocaine; Quinpirole; 7-OH-DPAT; Drug discrimination; Dopamine receptors; Rhesus monkey **54**, 97
- Self-administration**; Gamma-hydroxybutyrate; Rhesus monkeys; Drug discrimination; Abuse potential; Dependence potential **54**, 137
- Sex differences**; Illicit drugs; NHSDA; Opportunity; Transitions **54**, 117
- Sex risk**; Condom use; Heterosexually active drug users; HIV intervention **54**, 57
- Smokers**; Cotinine replacement; Patch treatment **54**, 111
- Smoking**; Alcohol abuse; Alcohol dependence; Nicotine; Treatment **54**, 259
- Smoking**; Cessation; Youth; Unemployed; Student **54**, 251
- South western Sydney**; Fatal overdose; Heroin purity **54**, 155
- Street outreach**; Substance abuse; HIV/AIDS prevention; Recruitment **54**, 1
- Student**; Smoking; Cessation; Youth; Unemployed **54**, 251
- Subjective effects**; Dynorphin; Opioid; κ Agonist **54**, 87
- Substance abuse**; CD4+ lymphocyte decline; Drug users; HIV; Heroin **54**, 145
- Substance abuse**; HIV/AIDS prevention; Street outreach; Recruitment **54**, 1
- Substance abuse**; Intravenous; Human immunodeficiency virus **54**, 83
- Substance abuse**; Methadone-maintenance; Race; Gender; Equivalence **54**, 11
- Subtypes**; Cocaine dependence; Treatment outcome; Electrophysiology; QEEG; Neurometrics; Comorbidity **54**, 35
- Transitions**; Illicit drugs; NHSDA; Opportunity; Sex differences **54**, 117
- Treatment**; Alcohol abuse; Alcohol dependence; Nicotine; Smoking **54**, 259
- Treatment compliance**; Naltrexone; Opioid-dependence; Treatment; Contingency management **54**, 127
- Treatment efficacy**; Cocaine treatment; Methadone treatment; Clinical trial **54**, 207
- Treatment**; Naltrexone; Opioid-dependence; Contingency management; Treatment compliance **54**, 127
- Treatment outcome**; Cocaine dependence; Subtypes; Electrophysiology; QEEG; Neurometrics; Comorbidity **54**, 35
- Ultimatum**; Addiction Severity Index; Coercion; Pressure to enter treatment **54**, 63
- Unemployed**; Smoking; Cessation; Youth; Student **54**, 251
- Vouchers**; Contingency management; Detoxification; Methadone; Benzodiazepines **54**, 69
- Youth**; Smoking; Cessation; Unemployed; Student **54**, 251

